CY1118482T1 - Αντιδοτα για τους αναστολεις του παραγοντα χα και μεθοδοι για χρηση αυτων - Google Patents

Αντιδοτα για τους αναστολεις του παραγοντα χα και μεθοδοι για χρηση αυτων

Info

Publication number
CY1118482T1
CY1118482T1 CY20161101020T CY161101020T CY1118482T1 CY 1118482 T1 CY1118482 T1 CY 1118482T1 CY 20161101020 T CY20161101020 T CY 20161101020T CY 161101020 T CY161101020 T CY 161101020T CY 1118482 T1 CY1118482 T1 CY 1118482T1
Authority
CY
Cyprus
Prior art keywords
factor
methods
antidotes
suspensions
conditions
Prior art date
Application number
CY20161101020T
Other languages
English (en)
Inventor
Genmin Lu
David R Phillips
Patrick Andre
Uma Sinha
Original Assignee
Portola Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals, Inc. filed Critical Portola Pharmaceuticals, Inc.
Publication of CY1118482T1 publication Critical patent/CY1118482T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με αντίδοτα αντιπηκτικής αγωγής που στοχεύει στον παράγοντα Xa. Τα αντίδοτα είναι πρωτεϊνικά παράγωγα του παράγοντα Xa που προσδένονται στους αναστολείς του παράγοντα Xa και έτσι τους εξουδετερώνουν ουσιαστικά αλλά δεν συναθροίζονται σε σύμπλοκο προθρομβινάσης. Τα παράγωγα που περιγράφονται εδώ στερούνται ή έχουν μειωμένη εσωτερική αντιπηκτική δραστηριότητα. Στο παρόν αποκαλύπτονται μέθοδοι για τη διακοπή ή παρεμπόδιση της αιμορραγίας σε έναν ασθενή ο οποίος βρίσκεται επί του παρόντος σε θεραπευτική αντιπηκτική αγωγή με αναστολέα του παράγοντα Xa.
CY20161101020T 2007-09-28 2016-10-12 Αντιδοτα για τους αναστολεις του παραγοντα χα και μεθοδοι για χρηση αυτων CY1118482T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97634307P 2007-09-28 2007-09-28
US9057408P 2008-08-20 2008-08-20
PCT/US2008/078014 WO2009042962A2 (en) 2007-09-28 2008-09-26 Antidotes for factor xa inhibitors and methods of using the same

Publications (1)

Publication Number Publication Date
CY1118482T1 true CY1118482T1 (el) 2017-07-12

Family

ID=40481812

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161101020T CY1118482T1 (el) 2007-09-28 2016-10-12 Αντιδοτα για τους αναστολεις του παραγοντα χα και μεθοδοι για χρηση αυτων
CY20201100715T CY1123504T1 (el) 2007-09-28 2020-08-04 Αντιδοτα για τους αναστολεις του παραγοντα χα και μεθοδοι χρησεως αυτων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100715T CY1123504T1 (el) 2007-09-28 2020-08-04 Αντιδοτα για τους αναστολεις του παραγοντα χα και μεθοδοι χρησεως αυτων

Country Status (27)

Country Link
US (8) US8153590B2 (el)
EP (4) EP2915564B1 (el)
JP (6) JP5637561B2 (el)
KR (4) KR20170100071A (el)
CN (4) CN102559644B (el)
AU (6) AU2008304192B9 (el)
BR (2) BRPI0816837B1 (el)
CA (1) CA2697583C (el)
CY (2) CY1118482T1 (el)
DK (3) DK2193196T3 (el)
ES (3) ES2597436T3 (el)
FR (1) FR20C1045I2 (el)
HK (1) HK1210443A1 (el)
HR (2) HRP20161255T1 (el)
HU (4) HUE050063T2 (el)
IL (4) IL203993A (el)
LT (3) LT2193196T (el)
MX (1) MX2010003095A (el)
NL (1) NL301063I2 (el)
NO (2) NO2019040I1 (el)
NZ (1) NZ583944A (el)
PL (3) PL3078743T3 (el)
PT (3) PT3078743T (el)
SG (1) SG185263A1 (el)
SI (3) SI3078743T1 (el)
WO (1) WO2009042962A2 (el)
ZA (2) ZA201002039B (el)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
JP5227311B2 (ja) 2006-05-05 2013-07-03 ミレニアム ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤
CA2697583C (en) * 2007-09-28 2016-04-12 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
US8268783B2 (en) 2007-09-28 2012-09-18 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
CA2743496C (en) * 2008-11-14 2018-03-27 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
SI2379096T1 (sl) * 2008-12-19 2020-03-31 Baxalta GmbH Zaviralci TFPI in postopki uporabe
CA2767858C (en) * 2009-07-15 2019-02-12 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
ES2620421T3 (es) * 2009-10-30 2017-06-28 Senova Gesellschaft für Biowissenschaft und Technik mbH Peptidasas acopladas a polímero
WO2011084652A2 (en) * 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor xa inhibitor
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
WO2011115712A2 (en) 2010-03-19 2011-09-22 Baxter International Inc Tfpi inhibitors and methods of use
TW201221128A (en) 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
TW201240664A (en) * 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
WO2012098089A1 (en) 2011-01-19 2012-07-26 Bayer Pharma Aktiengesellschaft Binding proteins to inhibitors of coagulation factors
FR2972114B1 (fr) * 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
PE20140964A1 (es) 2011-03-30 2014-08-17 Boehringer Ingelheim Int Antidotos anticoagulantes
EP2760887A4 (en) * 2011-09-30 2015-06-10 Philadelphia Children Hospital COMPOSITIONS AND METHODS OF HEMOSTASE MODULATION
UA116336C2 (uk) * 2011-11-29 2018-03-12 Перосфіе Фармасьютікалз Інк. Агенти, реверсуючі дію антикоагулянтів
CN104254603A (zh) * 2012-02-14 2014-12-31 博尔托拉制药公司 用于制备xa因子抑制剂的重组解毒剂的方法
US20160015793A1 (en) * 2012-02-16 2016-01-21 Portola Pharmacueticals, Inc. Modulation of factor xa inhibitor mediated blood loss by partial and transient administration of antidote
DK2827883T3 (da) 2012-03-21 2019-07-29 Baxalta GmbH Tfpi-inhibitorer og fremgangsmåder til anvendelse
PT2861614T (pt) * 2012-06-14 2017-01-26 Portola Pharm Inc Método para a purificação de derivados do fator xa recombinantes
MX365612B (es) * 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
FR3000895B1 (fr) * 2013-01-11 2017-02-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques
US20150352194A1 (en) * 2013-01-24 2015-12-10 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
FR3007410B1 (fr) * 2013-06-21 2016-05-27 Lab Francais Du Fractionnement Facteur x depourvu de domaine gla
EP3049434A1 (en) * 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
CA2928762A1 (en) * 2013-11-01 2015-05-07 The Children's Hospital Of Philadelphia Compositions and methods for increasing the half-life of factor xa
BR112016027649A2 (pt) 2014-05-26 2017-08-15 Academisch Ziekenhuis Leiden Proteínas prohemostáticas para o tratamento de hemorragia
WO2016019145A1 (en) * 2014-07-31 2016-02-04 Haemonetics Corporation Detection and classification of an anticoagulant using a clotting assay
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
EP3182993B1 (en) 2014-08-20 2020-07-01 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
CN105030703B (zh) * 2015-06-23 2018-03-23 上海旭东海普药业有限公司 一种防治疗栓塞性疾病的利伐沙班片及其制备方法
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
US20190046450A1 (en) 2016-02-24 2019-02-14 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
US10640822B2 (en) 2016-02-29 2020-05-05 Iridia, Inc. Systems and methods for writing, reading, and controlling data stored in a polymer
US10438662B2 (en) 2016-02-29 2019-10-08 Iridia, Inc. Methods, compositions, and devices for information storage
JP2019512480A (ja) * 2016-02-29 2019-05-16 イリディア・インコーポレイテッドＩｒｉｄｉａ， Ｉｎｃ． 情報保存のための方法、組成物およびデバイス
US10859562B2 (en) 2016-02-29 2020-12-08 Iridia, Inc. Methods, compositions, and devices for information storage
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
MX2018015873A (es) 2016-06-17 2019-08-12 Portola Pharm Inc Preparacion de derivados del factor xa.
WO2018115235A1 (en) 2016-12-22 2018-06-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antidotes to anti-coagulant drugs allowing diagnosis and treatment
CN110325550B (zh) 2016-12-23 2024-03-08 诺华股份有限公司 因子xi抗体和使用方法
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3672520A4 (en) * 2017-08-21 2021-06-30 Allele Biotechnology And Pharmaceuticals, Inc. LIGHT ABSORBING COMPOSITIONS AND METHODS OF USE
US11787874B2 (en) 2017-11-15 2023-10-17 Novo Nordisk A/S Factor X binders enhancing FX activation
WO2019246094A1 (en) * 2018-06-19 2019-12-26 Portola Pharmaceuticals, Inc. Antidotes to factor xa inhibitors
EP3838265A4 (en) * 2018-08-14 2022-05-11 Jiangsu Hengrui Medicine Co., Ltd. INJECTABLE PHARMACEUTICAL COMPOSITION AND METHOD FOR PREPARATION
US11655465B1 (en) 2019-05-02 2023-05-23 Iridia, Inc. Enzymes and systems for synthesizing DNA
WO2021026254A2 (en) * 2019-08-08 2021-02-11 Portola Pharmaceuticals, Inc. Compositions and methods for preparing factor xa and derivatives
US11837302B1 (en) 2020-08-07 2023-12-05 Iridia, Inc. Systems and methods for writing and reading data stored in a polymer using nano-channels
CN113484386B (zh) * 2021-05-21 2024-02-13 郑州轻工业大学 一种金属聚酞菁纳米材料的制备方法及其应用，适配体传感器及其制备方法
CN114681597A (zh) * 2022-03-11 2022-07-01 兆科药业（合肥）有限公司 蝰蛇蛇毒血凝酶在制备用于逆转凝血因子Xa抑制剂的抗凝作用的药物中的应用
CN116327627A (zh) * 2023-03-10 2023-06-27 四川大学 一种四面体框架核酸-光甘草定复合物及其在皮肤美白方面的用途

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH596313A5 (el) * 1975-05-30 1978-03-15 Battelle Memorial Institute
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3546806C2 (el) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5686073A (en) 1990-05-23 1997-11-11 The University Of Iowa Research Foundation Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5278144A (en) 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
JPH06505486A (ja) 1991-02-07 1994-06-23 モレキュメティクス，リミティド βターンおよびβバルジのコンフォメーション的に制限された模倣物およびそれらを含有するペプチド
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
ES2182822T3 (es) 1991-09-13 2003-03-16 Chiron Corp Composiciones de polipeptidos inmunorreactivos del virus de la hepatitis c.
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
JPH07507769A (ja) 1992-03-20 1995-08-31 コアー・セラピュティックス・インコーポレーテッド Ｘ因子のグリコシル化媒介による阻害
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
WO1995011984A2 (en) 1993-10-25 1995-05-04 Canji, Inc. Recombinant adenoviral vector and methods of use
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
DE4430205A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US6709659B1 (en) 1996-08-02 2004-03-23 Zymogenetics, Inc. Antibodies that bind testis-specific insulin homolog polypeptides
SE9604744D0 (sv) 1996-12-20 1996-12-20 Pharmacia & Upjohn Ab A modified coagulation agent
AT405517B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
WO1998039456A1 (en) * 1997-03-07 1998-09-11 Washington University Factor x variant
JPH1149800A (ja) 1997-06-05 1999-02-23 Fujimori Kogyo Kk アンヒドロトロンビンの合成方法
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
CA2347833A1 (en) 1998-11-18 2000-05-25 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US6258559B1 (en) 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US6858599B2 (en) 1999-06-30 2005-02-22 Mochida Pharmaceutical Co., Ltd. Tricyclic compound having spiro union
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
EP1259485B1 (en) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
WO2001068605A1 (en) 2000-03-13 2001-09-20 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
EP2298789B1 (en) 2000-09-08 2012-03-14 Schering Corporation Mammalian genes; related reagents and methods
US7070740B1 (en) 2000-09-28 2006-07-04 Beckman Coulter, Inc. Method and apparatus for processing biomolecule arrays
US20030064414A1 (en) 2001-03-30 2003-04-03 Benecky Michael J. Rapid assessment of coagulation activity in whole blood
WO2002090599A1 (en) 2001-05-09 2002-11-14 Genetic Id, Inc. Universal microarray system
US6989267B2 (en) 2001-07-02 2006-01-24 Agilent Technologies, Inc. Methods of making microarrays with substrate surfaces having covalently bound polyelectrolyte films
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
CN1480466A (zh) * 2002-09-03 2004-03-10 �й������ž�����ҽѧ��ѧԺ����ҽ 一类溶栓抗凝双功能融合蛋白及应用
US20040198660A1 (en) 2002-11-06 2004-10-07 Petersen Lars Christian Tissue factor antagonist and protein C polypeptide compositions
US7247654B2 (en) 2003-06-04 2007-07-24 Bristol-Myers Squibb Company 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
JP2007527539A (ja) 2004-03-05 2007-09-27 ザ スクリプス リサーチ インスティテュート ハイスループットグリカンマイクロアレイ
JP4441336B2 (ja) 2004-06-11 2010-03-31 日本碍子株式会社 マイクロアレイの製造方法
US9223929B2 (en) 2005-03-14 2015-12-29 The California Institute Of Technology Method and apparatus for detection, identification and quantification of single-and multi-analytes in affinity-based sensor arrays
US7119179B1 (en) 2005-03-21 2006-10-10 Los Alamos National Security, Llc Preparation of high nitrogen compound and materials therefrom
WO2006102687A1 (en) 2005-03-22 2006-09-28 The Trustees Of Columbia University In The City Of New York A liposome-based microarray and methods of use thereof
ATE549317T1 (de) 2005-11-08 2012-03-15 Millennium Pharm Inc Pharmazeutische salze und polymorphe aus n-(5- chloro-2-pyridinyl)-2-ää4- ä(dimethylamino)iminomethylübenzoylüaminoü-5- methoxy-benzamid, einem faktor-xa-hemmer
MX2008006313A (es) 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
US20070111322A1 (en) 2005-11-15 2007-05-17 Lin-Cheng Yang Novel method of using inject printing for creating microarrays
EP1820508A1 (en) * 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
US8268783B2 (en) * 2007-09-28 2012-09-18 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
CA2697583C (en) * 2007-09-28 2016-04-12 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
CA2743496C (en) * 2008-11-14 2018-03-27 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
WO2010070137A1 (en) 2008-12-19 2010-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
CA2767858C (en) 2009-07-15 2019-02-12 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same

Also Published As

Publication number Publication date
BRPI0816837A2 (pt) 2020-08-18
BRPI0816837B1 (pt) 2022-10-18
AU2013205326A8 (en) 2013-06-06
HRP20161255T1 (hr) 2016-12-02
AU2008304192B2 (en) 2014-05-15
AU2014210620A1 (en) 2014-08-28
DK2193196T3 (en) 2016-11-07
US20200276280A1 (en) 2020-09-03
ES2796623T3 (es) 2020-11-27
EP3078743A1 (en) 2016-10-12
SI2915564T1 (sl) 2021-03-31
CN102559644A (zh) 2012-07-11
US20120269788A1 (en) 2012-10-25
DK3078743T3 (da) 2020-08-10
US20090098119A1 (en) 2009-04-16
CN102533702A (zh) 2012-07-04
IL264886B (en) 2020-03-31
FR20C1045I1 (el) 2020-10-30
HUE052423T2 (hu) 2021-04-28
SG185263A1 (en) 2012-11-29
IL203993A (en) 2017-11-30
PL2915564T3 (pl) 2021-07-19
PL3078743T3 (pl) 2020-11-02
EP2915564B1 (en) 2020-11-04
EP3078743B1 (en) 2020-06-24
KR20200009131A (ko) 2020-01-29
LTPA2020540I1 (lt) 2021-01-11
CN102559644B (zh) 2015-03-25
AU2017200212A1 (en) 2017-02-02
AU2021218033A1 (en) 2021-09-09
KR20100077172A (ko) 2010-07-07
JP2017043632A (ja) 2017-03-02
US20150057228A1 (en) 2015-02-26
AU2008304192B9 (en) 2024-02-01
DK2915564T3 (da) 2021-02-08
PT2915564T (pt) 2021-02-09
NO2020033I1 (no) 2020-09-23
ZA201002039B (en) 2015-11-25
CN103446579A (zh) 2013-12-18
KR20170100071A (ko) 2017-09-01
JP2020109113A (ja) 2020-07-16
NL301063I2 (nl) 2021-06-23
FR20C1045I2 (fr) 2021-08-27
KR102271404B1 (ko) 2021-07-02
IL255397B (en) 2019-03-31
CN101802188A (zh) 2010-08-11
US20240082367A1 (en) 2024-03-14
NO2019040I1 (no) 2019-11-08
US10675335B2 (en) 2020-06-09
AU2019204123A1 (en) 2019-07-04
KR101698214B1 (ko) 2017-01-20
HUS2000057I1 (hu) 2021-01-28
AU2014210620B2 (en) 2016-05-12
NL301063I1 (el) 2020-09-16
HK1210443A1 (en) 2016-04-22
MX2010003095A (es) 2010-04-09
WO2009042962A2 (en) 2009-04-02
EP3824902A1 (en) 2021-05-26
AU2008304192A1 (en) 2009-04-02
AU2013205326A1 (en) 2013-05-09
NZ583944A (en) 2012-06-29
JP2018100290A (ja) 2018-06-28
JP2014218521A (ja) 2014-11-20
HUE050063T2 (hu) 2020-11-30
JP6047127B2 (ja) 2016-12-21
PT2193196T (pt) 2016-10-24
IL272926A (en) 2020-04-30
WO2009042962A3 (en) 2009-06-04
JP5637561B2 (ja) 2014-12-10
JP6300885B2 (ja) 2018-03-28
HUE031647T2 (en) 2017-07-28
KR20160025038A (ko) 2016-03-07
JP2010539945A (ja) 2010-12-24
US20140079684A1 (en) 2014-03-20
SI3078743T1 (sl) 2020-08-31
BR122022001846B1 (pt) 2022-12-27
US11839646B2 (en) 2023-12-12
PL2193196T3 (pl) 2017-07-31
US20160354449A1 (en) 2016-12-08
HRP20201071T1 (hr) 2020-10-30
PT3078743T (pt) 2020-07-15
US20140044773A1 (en) 2014-02-13
KR102069498B1 (ko) 2020-01-23
US8153590B2 (en) 2012-04-10
AU2008304192A2 (en) 2010-04-08
ES2849426T3 (es) 2021-08-18
US9062298B2 (en) 2015-06-23
ES2597436T3 (es) 2017-01-18
IL255397A0 (en) 2017-12-31
CN101802188B (zh) 2013-08-21
EP2915564A1 (en) 2015-09-09
CN103446579B (zh) 2015-04-22
LT2193196T (lt) 2016-12-12
US8889129B2 (en) 2014-11-18
US8455441B2 (en) 2013-06-04
LT3078743T (lt) 2020-09-25
SI2193196T1 (sl) 2017-01-31
US9388401B2 (en) 2016-07-12
CY1123504T1 (el) 2021-06-25
EP2193196B1 (en) 2016-07-13
CA2697583C (en) 2016-04-12
IL203993A0 (en) 2011-07-31
EP2193196A2 (en) 2010-06-09
WO2009042962A9 (en) 2009-09-11
ZA201406514B (en) 2016-10-26
JP2022153574A (ja) 2022-10-12
CA2697583A1 (en) 2009-04-02
LTC3078743I2 (lt) 2022-06-10

Similar Documents

Publication Publication Date Title
CY1118482T1 (el) Αντιδοτα για τους αναστολεις του παραγοντα χα και μεθοδοι για χρηση αυτων
CY1122685T1 (el) Μορφες δοσολογιας της απιξαμπανης
CY1117340T1 (el) Κυτταροτοξικα παραγωγα βενζοδιαζεπινης
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1116797T1 (el) Αναστολεις φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1119213T1 (el) Πρωτεϊνη p75ntr συνδεσης νευροτροφινης για θεραπευτικη χρηση
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1116064T1 (el) Συστασεις αναστολεα ddp iv
CY1119399T1 (el) Aντι-dkk-1 αντισωματα
EA201100084A1 (ru) Сшиваемая полимерная композиция
AR089339A1 (es) Articulos para fumar, y otros articulos con emanacion de flujo
CY1121244T1 (el) Συνδυασμος αναστολεα τελομερασης και γεμσιταβινής για τη θεραπεια του καρκινου
CY1118832T1 (el) Γελη πολλαπλου σκοπου για κολπικη ξηροτητα με αμεσο και επιβραδυνομενο αποτελεσμα
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CY1122813T1 (el) Διαλυτος cd33 για την αγωγη μυελοδυσπλαστικων συνδρομων (μds)
CY1121267T1 (el) Τροποποιημενες σερπινες για τη θεραπευτικη αγωγη αιμορραγικων διαταραχων
AR084330A1 (es) Polimeros a base de etileno y procesos para formarlos
CR20110032A (es) Derivados de tiofeno y tiazol y su uso como inhibidores de p13k
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
CL2012003385A1 (es) Tratamiento para la incontinencia.
BRPI0819258A2 (pt) alguns derivados de 2-pirazinona e seu uso como inibidores da elastase neutrófila
CY1116802T1 (el) Ετεροκυκλικες ενωσεις
CY1123596T1 (el) Θεραπεια της κοκκιδιωσης με ενδομυϊκες συνθεσεις τριαζινης